Physician profile
Parth Shah
NPI 1417509241
$2,315.16
in general payments reported to CMS, 2019-2025
10 companies · $1,483 in 2025
The $1,483 reported for 2025 was more than what 90% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $15.47 · 2024: $816 · 2025: $1,483.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,957 · Education: $358.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,957.01 |
| Education | $358.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $722.93 | 2024-2025 | Ensite, Cardiomems, Thoratec Heartmate 3 Lvas Implant Kit |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $393.81 | 2024-2025 | Lifevest |
| E.R. Squibb & Sons, L.L.C. | $378.59 | 2024-2025 | Camzyos, Eliquis |
| Astrazeneca Pharmaceuticals LP | $211.00 | 2023-2025 | Farxiga, Lokelma, Brilinta |
| Pfizer INC. | $197.62 | 2024-2025 | |
| Abiomed | $177.68 | 2024-2025 | Impella |
| Impulse Dynamics (USA) INC. | $101.49 | 2025 | Optimizer |
| Scpharmaceuticals INC. | $76.54 | 2025 | |
| Mannkind Corporation | $27.97 | 2025 | |
| Janssen Pharmaceuticals, INC | $27.53 | 2024 | Xarelto |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Parth Shah listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.